Title :

In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against pneumocystis pneumonia

Author(s) :

Aliouat, El Moukhtar [Auteur]
106189|||Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL] (VALID)
Dei Cas, Eduardo [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Gantois, Nausicaa [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Pottier, Muriel [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
498252|||Lille Inflammation Research International Center - U 995 [LIRIC] (OLD)
Pinçon, Claire [Auteur]
221576|||Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS] (VALID)
Hawser, S. [Auteur]
Lier, A. [Auteur]
Huang, D. B. [Auteur]

Journal title :

European Journal of Clinical Microbiology & Infectious Diseases

Abbreviated title :

Eur. J. Clin. Microbiol. Infect. Dis.

Volume number :

37

Pages :

409-415

Publication date :

2018-03

ISSN :

0934-9723

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Pneumocystis pneumonia is a serious complication that may affect immunosuppressed patients. The absence of reliable and safe therapeutic alternatives to trimethoprim-sulfamethoxazole (TMP/SMX) justifies the search for more ...
Show more >Pneumocystis pneumonia is a serious complication that may affect immunosuppressed patients. The absence of reliable and safe therapeutic alternatives to trimethoprim-sulfamethoxazole (TMP/SMX) justifies the search for more effective and less toxic agents. In this study, the in vitro and in vivo anti-Pneumocystis jirovecii activity of iclaprim, a diaminopyrimidine compound that exerts its antimicrobial activity through the inhibition of dihydrofolate reductase (DHFR), as does TMP, was evaluated alone or in combination with SMX. The antimicrobial activity of iclaprim was tested in vitro using an efficient axenic culture system, and in vivo using P. carinii endotracheally inoculated corticosteroid-treated rats. Animals were orally administered iclaprim (5, 25, 50 mg/kg/day), iclaprim/SMX (5/25, 25/125, 50/250 mg/kg/day), TMP (50 mg/kg/day), or TMP/SMX (50/250 mg/kg/day) once a day for ten consecutive days. The in vitro maximum effect (Emaxmax50max505050Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T16:49:43Z
2024-03-01T15:00:36Z
2024-03-01T15:24:50Z